Latest Intervacc News & Updates

See the latest news and media coverage for Intervacc. We track all announcements, press releases, and industry mentions in real time, all in one place.

Intervacc

Swedish veterinary vaccine and pharmaceutical company

intervacc.se

Headquarters: Stockholm, Sweden
Company type: Public company
Number of employees: 21–50
Industry: Pharmaceuticals

Last updated August 20

Latest news about Intervacc

In short: Intervacc advanced Strangvac with EMA filing, Iceland approval, New Zealand export and US trials.

Company announcements

August 20 Intervacc

Intervacc publishes interim report January-June 2026

The company reports for the half-year but presents strategic progress for Strangvac and expansion to the USA and Iceland.

May 13 Intervacc

Intervacc publishes interim report for the first quarter of 2026

Net sales decreased and operating profit deteriorated.

February 17 Intervacc

Intervacc publishes year-end report January–December 2025

Net sales increase to 20,087 TSEK, operating result worsens to -83,501 TSEK. Strangvac expands in Europe and US studies are ongoing. New CEO and sales manager are recruited.

February 5 Intervacc

Intervacc announces change of CEO

Jonas Sohlman leaves the role. Carl-Johan Dalsgaard is appointed new CEO with immediate effect. He has extensive experience from drug development and biotech.

Media coverage

August 19 Finanznachrichten

Intervacc AB: Interim report January - June 2026

This information is information that Intervacc AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for...

July 30 Zone Bourse

Intervacc submits a type II variation application to the EMA to extend the duration of immunity of Strangvac to 12 months

Intervacc AB has submitted a type II variation application to the European Medicines Agency for Strangvac, the innovative vaccine from the...

May 12 Finanznachrichten

Intervacc AB: Interim report January - March 2026

The interim report for the period January - March 2026 is attached to this press release and is available on the company's website This information...

March 19 Lantbruksnytt

Breakthrough protection against Streptococcus suis infection in piglets

Intervacc is first in the world to show that piglets were protected against the virulent and seriously disease-causing S. suis sequence types 1 and 16 (serotype 2...

Never miss news about Intervacc

Track Intervacc and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Intervacc competitors & trending companies

Browse news for competitors to Intervacc and other trending companies.